Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury.

Fiche publication


Date publication

avril 2012

Journal

Anticancer research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Pr NERICH Virginie, Pr PIVOT Xavier, Dr CURTIT Elsa, Dr THIERY-VUILLEMIN Antoine, Dr DEMARCHI Martin


Tous les auteurs :
Curtit E, Chaigneau L, Pauchot J, Nguyen T, Nerich V, Bazan F, Thiery-Vuillemin A, Demarchi M, Pivot X, Villanueva C

Résumé

Anthracycline extravasation is an uncommon but very serious complication. Very few data are available in the literature concerning the consequences and the management of extravasation of liposomal doxorubicin. This report describes the cases of two patients with liposomal doxorubicin extravasation who developed irritant reaction without vesicant or necrotic lesions. It is concordant with other cases described in the literature and suggests that extravasation of liposomal doxorubicin can be relatively well tolerated. The process applied to extravasations of irritant and non-vesicant agents could be used to manage extravasations of liposomal doxorubicin.

Mots clés

Aged, Doxorubicin, adverse effects, Extravasation of Diagnostic and Therapeutic Materials, Female, Humans, Irritants, adverse effects, Middle Aged

Référence

Anticancer Res.. 2012 Apr;32(4):1481-3